deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00648739

Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM

A Phase I/II Open Label Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of ALXN6000 In Patients With Relapsing Or Refractory B-Cell Chronic Lymphocytic Leukemia Or Multiple Myeloma

Sponsor: Alexion Pharmaceuticals, Inc.

Conditions B-cell Chronic Lymphocytic Leukemia Multiple Myeloma
Interventions Samalizumab
Updated 11 times since 2017 Last updated: Feb 12, 2019 Started: Jun 19, 2008 Primary completion: Dec 14, 2010 Completion: Dec 14, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was terminated by the Sponsor for administrative reasons and not due to any safety concerns.

Other terminated trials from Alexion Pharmaceuticals, Inc.

More terminations from Alexion Pharmaceuticals, Inc.

A PHASE1/PHASE2 clinical study on B-cell Chronic Lymphocytic Leukemia and Multiple Myeloma, this trial is terminated or withdrawn. The trial is conducted by Alexion Pharmaceuticals, Inc. and has accumulated 11 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Apr 2019 · 10 months · monthly snapshotCompleted~Apr 2019 – ~Nov 2020 · 19 months · monthly snapshotTerminated~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Apr 2023 · 16 months · monthly snapshotTerminated~Apr 2023 – ~Dec 2023 · 8 months · monthly snapshotTerminated~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Dec 2023 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Apr 2023 — Dec 2023 [monthly]

    Terminated PHASE1_PHASE2

  5. Dec 2021 — Apr 2023 [monthly]

    Terminated PHASE1_PHASE2

▶ Show 6 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE1_PHASE2

  2. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

  3. Apr 2019 — Nov 2020 [monthly]

    Terminated PHASE1_PHASE2

    Status: Completed → Terminated

  4. Jun 2018 — Apr 2019 [monthly]

    Completed PHASE1_PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

  6. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Alexion Pharmaceuticals, Inc.
Data source: Alexion Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations